| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 10 Mar 2025 | 5 Mar 2025 |
| Supriya Lifescience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/03/2025 inter alia to consider and approve With reference to above subject matter and pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we would like to inform you that the meeting of the Board of Directors of the Company will be held on Monday March 10 2025 at 11.30 a.m at the registered office of the Company to consider and transact the following businesses: 1. Appointment of Company Secretary and Compliance Officer of the Company; 2. Any other matter with the permission of the chair. Kindly take the above information on your records. With reference to above subject matter and pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors of the Company at their meeting held on Monday, March 10, inter alia considered and approved the following businesses: 1. Appointment of Ms. Prachi Sathe bearing Membership No. A-70252 as Company Secretary and Compliance Officer of the Company with effect from March 10, 2025, on the basis of recommendations received from the Nomination and Remuneration Committee of the Company; 2. Any other matters incidental with the appointment of Company Secretary and Compliance Officer of the Company; Brief profile as per SEBI circular is attached. The Meeting of the Board of Directors of the Company commenced at 11.30 a.m. and concluded at 12.00 noon. Kindly take the same on record. (As Per Bse Announcement Dated on 10.03.2025) | ||
| Board Meeting | 24 Jan 2025 | 16 Jan 2025 |
| Supriya Lifescience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/01/2025 inter alia to consider and approve the Unaudited Financial Results of the Company for the quarter and nine months ended December 31 2024. Please find the attachment. Please be informed that the Board of Directors of the Company at its Meeting held on Friday, January 24, 2025, has approved the Unaudited Financial Results and appointed Directors as per attachment. (As Per BSE Announcement Dated on 24/01/2025) | ||
| Board Meeting | 28 Oct 2024 | 21 Oct 2024 |
| Supriya Lifescience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/10/2024 inter alia to consider and approve the Unaudited Financial Results of the Company for the quarter and half year ended September 30 2024 Pursuant to Regulation 33 read with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please be informed that the Board of Directors of the Company at its Meeting held on Monday, October 28, 2024, inter-alia considered and approved the Unaudited Financial Results for the quarter and half year ended September 30, 2024. Read less.. Please find attachemnt. (As Per BSE Announcement Dated on 28.10.2024) | ||
| Board Meeting | 10 Aug 2024 | 3 Aug 2024 |
| Supriya Lifescience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2024 inter alia to consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30 2024. Pursuant to Regulation 33 read with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please be informed that the Board of Directors of the Company at its Meeting held on Saturday, August 10, 2024, inter-alia, has 1. Considered and approved the Unaudited Financial Results for the Quarter ended June 30, 2024 2. Approved the additional Capital Expenditure at Ambernath site for CDMO facility. Read less.. Please find the attachment. (As Per BSE Announcement Dated on 10.08.2024) | ||
| Board Meeting | 28 May 2024 | 20 May 2024 |
| Supriya Lifescience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2024 inter alia to consider and approve the Audited Financial Results of the Company for the quarter and year ended March 31 2024 and to recommend dividend if any for the financial year ended March 31 2024. Considered and approved a dividend of Rs. 0.80 per equity shares of Rs. 2/- each (As Per BSE Announcement dated on 28.05.2024) | ||
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
